Tolerability-guided Dose Adjustment of Afatinib Reduces Adverse Events

Share this content:
Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy.
Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy.

Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy in patients with advanced epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), according to results from a study presented at the European Lung Cancer Conference (ELCC) 2016.1

The U.S. Food and Drug Administration (FDA)-approved dose for first-line afatinib in patients with EGFR mutation-positive NSCLC is 40 mg/day; however, the dose can be adjusted based on individual tolerability. Therefore, researchers sought to assess the impact of afatinib dose adjustment on adverse events, pharmacokinetics, and progression-free survival.

For the post-hoc analysis, researchers examined data from the LUX-Lung 3 and LUX-Lung 6 studies, which included 229 and 239 afatinib-treated patients, respectively. Participants who experienced a treatment-related grade 3 or selected prolonged grade 2 adverse event with afatinib 40 mg could be dose-reduced in 10 mg increments to a minimum of 20 mg.

Results showed that dose reductions occurred in 53% of afatinib-treated patients in LUX-Lung 3 and 28% of afatinib-treated patients in LUX-Lung 6, with the majority experienced within the first 6 months of treatment.

Researchers found that dose reduction resulted in decreases in the incidence and severity of EGFR-mediated drug-related adverse events, such as diarrhea, rash/acne, stomatitis, and nail changes.

RELATED: Third Generation EGFR TKI Active in T790M-positive NSCLC

In terms of efficacy, median progression-free survival was 11.3 months for patients who dose reduced during the first 6 months of treatment compared with 11.0 months for those who did not dose reduce among patients of the LUX-Lung 3 trial (hazard ratio [HR], 1.25; 95% CI, 0.91-1.72). Similarly, median progression-free survival was 12.3 months and 11.0 months, respectively, in the LUX-Lung 6 study (HR, 1.00; 95% CI, 0.69-1.46).

Reference

  1. Schuler M, Yang J, Sequist LV, et al. Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). Poster presentation at: European Lung Cancer Conference 2016; April 13-16, 2016; Geneva, Switzerland.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs